Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial.

512Background: In the neoadjuvant NeoALTTO trial dual HER2 blockade with lapatinib (L) plus trastuzumab (T) combined with weekly paclitaxel significantly increased the pathologic complete response ...